Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment
Clinical studies have shown enhanced anticancer effects of combined inhibition of Src and MEK kinases. Development of multi-target drugs against Src and MEK is of potential therapeutic advantage against cancers. As a follow-up of our previous studies, and by using molecular docking method, we designed and synthesized a new series of 9-anilinoacridines containing phenyl-urea moieties as potential novel dual Src and MEK inhibitors. The anti-proliferative assays against K562 and HepG-2 tumor cells showed that most of the derivatives displayed good cytotoxicity in vitro. In particular, kinase inhibition assays showed that compound 8m inhibited Src (59.67%) and MEK (43.23%) at 10μM, and displayed moderate inhibitory activity against ERK and AKT, the downstream effectors of both Src and MEK. Moreover, compound 8m was found to induce K562 cells apoptosis. Structure-activity relationships of these derivatives were analyzed. Our study suggested that acridine scaffold, particularly compound 8m, is of potential interest for developing novel multi-target Src and MEK kinase inhibitors..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Bioorganic & medicinal chemistry - 24(2016), 2, Seite 261 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cui, Zhishan [VerfasserIn] |
|---|
| Links: |
|---|
| RVK: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1971306878 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1971306878 | ||
| 003 | DE-627 | ||
| 005 | 20230714181522.0 | ||
| 007 | tu | ||
| 008 | 160212s2016 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20160430 |
| 035 | |a (DE-627)OLC1971306878 | ||
| 035 | |a (DE-599)GBVOLC1971306878 | ||
| 035 | |a (PRQ)p831-4bae287508b737cf8ad48f68387fa3a94c673efa2773eb26ecccb3e3aa2ae9a30 | ||
| 035 | |a (KEY)0240099520160000024000200261designsynthesisandevaluationofacridinederivativesa | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a VA 2619 |q AVZ |2 rvk | ||
| 100 | 1 | |a Cui, Zhishan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Clinical studies have shown enhanced anticancer effects of combined inhibition of Src and MEK kinases. Development of multi-target drugs against Src and MEK is of potential therapeutic advantage against cancers. As a follow-up of our previous studies, and by using molecular docking method, we designed and synthesized a new series of 9-anilinoacridines containing phenyl-urea moieties as potential novel dual Src and MEK inhibitors. The anti-proliferative assays against K562 and HepG-2 tumor cells showed that most of the derivatives displayed good cytotoxicity in vitro. In particular, kinase inhibition assays showed that compound 8m inhibited Src (59.67%) and MEK (43.23%) at 10μM, and displayed moderate inhibitory activity against ERK and AKT, the downstream effectors of both Src and MEK. Moreover, compound 8m was found to induce K562 cells apoptosis. Structure-activity relationships of these derivatives were analyzed. Our study suggested that acridine scaffold, particularly compound 8m, is of potential interest for developing novel multi-target Src and MEK kinase inhibitors. | ||
| 540 | |a Nutzungsrecht: Copyright © 2015 Elsevier Ltd. All rights reserved. | ||
| 700 | 1 | |a Li, Xi |4 oth | |
| 700 | 1 | |a Li, Lulu |4 oth | |
| 700 | 1 | |a Zhang, Bin |4 oth | |
| 700 | 1 | |a Gao, Chunmei |4 oth | |
| 700 | 1 | |a Chen, Yuzong |4 oth | |
| 700 | 1 | |a Tan, Chunyan |4 oth | |
| 700 | 1 | |a Liu, Hongxia |4 oth | |
| 700 | 1 | |a Xie, Weiyi |4 oth | |
| 700 | 1 | |a Yang, Ti |4 oth | |
| 700 | 1 | |a Jiang, Yuyang |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Bioorganic & medicinal chemistry |d Amsterdam [u.a.] : Elsevier, 1993 |g 24(2016), 2, Seite 261 |w (DE-627)171175506 |w (DE-600)1161284-8 |w (DE-576)038869047 |x 0968-0896 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2016 |g number:2 |g pages:261 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26707846 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_4305 | ||
| 936 | r | v | |a VA 2619 |
| 951 | |a AR | ||
| 952 | |d 24 |j 2016 |e 2 |h 261 | ||